A detailed history of Bank Of America Corp transactions in Genmab A/S stock. As of the latest transaction made, Bank Of America Corp holds 1,097,271 shares of GMAB stock, worth $25.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,097,271
Previous 1,082,547 1.36%
Holding current value
$25.3 Million
Previous $32.4 Million 14.84%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$25.13 - $30.27 $370,014 - $445,695
14,724 Added 1.36%
1,097,271 $27.6 Million
Q1 2024

May 15, 2024

BUY
$26.43 - $32.77 $5.11 Million - $6.34 Million
193,383 Added 21.75%
1,082,547 $32.4 Million
Q4 2023

Feb 14, 2024

SELL
$27.94 - $35.44 $207,650 - $263,390
-7,432 Reduced 0.83%
889,164 $28.3 Million
Q2 2023

Aug 14, 2023

SELL
$37.4 - $42.94 $3.68 Million - $4.23 Million
-98,477 Reduced 9.9%
896,596 $34.1 Million
Q1 2023

May 12, 2023

BUY
$34.88 - $43.22 $3.19 Million - $3.95 Million
91,462 Added 10.12%
995,073 $37.6 Million
Q4 2022

Feb 10, 2023

BUY
$33.8 - $47.06 $4.06 Million - $5.65 Million
120,160 Added 15.34%
903,611 $38.3 Million
Q3 2022

Nov 14, 2022

SELL
$31.52 - $373.61 $886,468 - $10.5 Million
-28,124 Reduced 3.47%
783,451 $25.2 Million
Q2 2022

Aug 12, 2022

SELL
$26.83 - $38.57 $1.03 Million - $1.49 Million
-38,545 Reduced 4.53%
811,575 $26.4 Million
Q1 2022

May 16, 2022

SELL
$30.95 - $39.68 $344,194 - $441,281
-11,121 Reduced 1.29%
850,120 $30.8 Million
Q4 2021

Feb 08, 2022

SELL
$35.87 - $47.12 $9.56 Million - $12.6 Million
-266,421 Reduced 23.63%
861,241 $34.1 Million
Q3 2021

Nov 15, 2021

BUY
$41.55 - $48.72 $1.62 Million - $1.9 Million
38,936 Added 3.58%
1,127,662 $49.3 Million
Q2 2021

Sep 13, 2021

BUY
$32.88 - $44.57 $35.8 Million - $48.5 Million
1,088,726 New
1,088,726 $44.5 Million

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $15.2B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.